Answers are grounded in this paper and cite their sources.
Pharmaceutical manufacturers have attempted to blunt the impact of drug copayments and coinsurance on patients by funding patient-assistance programs. But these programs may lead to higher drug prices, undermining the beneficial aspects of cost sharing.
No takes yet. Share an insight, caveat, or question.
David H. Howard (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: